|
Leonid Bajenov, Ph.D., M.D., a professor at the
Vakhidov Research Center of Surgery, Tashkent, Republic of Uzbekistan, has
published more than 300 scientific works. Dr. Bajenov is currently conducting
clinical trials of Coley Fluid.
Zuhal Butuner, OD, MSc, MBA, is a clinical and
regulatory advisor. Dr. Butuner was previously Senior Clinical Program Manager
at Biogen Inc., where she led and managed the team responsible for obtaining FDA
approval for the drug Avonex®.
Peter Coy, M.D., is a retired radiation oncologist,
formerly director of the Victoria Cancer Centre and clinical assistant professor
at the University of British Columbia. As chair of the lung cancer sub-committee
of the National Cancer Institute of Canada Clinical Trials Committee, Dr. Coy
was involved in the completion of five multi institutional clinical trials in
lung cancer using combinations of surgery, radiation, chemotherapy and
immunotherapy.
Hal Gunn, M.D., is a co-founder and chief executive
officer of the Centre for Integrated Healing, Vancouver, BC, a non-profit
organization funded in part by the Medical Services Plan of BC, the Canadian
Cancer Society, and the BC Cancer Agency. Dr. Gunn has used bacterial vaccines
in the treatment of cancer, and has a clinical appointment with the University
of British Columbia School of Medicine.
Kenneth
Wilson,
M.D., is a medical oncologist at the Vancouver Island Cancer Centre and a
clinical associate professor at the University of British Columbia. Dr. Wilson
has published more than 150 papers and communications, and is a member of the
American Society of Clinical Oncology and the Canadian Association of Medical
Oncologists.
|